

Theo van der Kwast

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1744416/theo-van-der-kwast-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

443 papers	34,425 citations	85 h-index	173 g-index
473 ext. papers	41,413 ext. citations	7.5 avg, IF	6.86 L-index

#	Paper	IF	Citations
443	Screening and prostate-cancer mortality in a randomized European study. <i>New England Journal of Medicine</i> , 2009 , 360, 1320-8	59.2	2828
442	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017 , 71, 618-629	10.2	1939
441	EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. <i>European Urology</i> , 2014 , 65, 124-37	10.2	1360
440	EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. <i>European Urology</i> , 2011 , 59, 61-71	10.2	1112
439	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>European Urology</i> , 2014 , 65, 467-79	10.2	965
438	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017 , 71, 630-642	10.2	924
437	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014 , 384, 2027-35	40	910
436	Prostate-cancer mortality at 11 years of follow-up. <i>New England Journal of Medicine</i> , 2012 , 366, 981-90	59.2	875
435	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. <i>Lancet Oncology, The</i> , 2010 , 11, 1066-73	21.7	646
434	Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. <i>American Journal of Roentgenology</i> , 2007 , 189, 323-8	5.4	461
433	Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. <i>Molecular Endocrinology</i> , 1991 , 5, 1396-404		429
432	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>European Urology</i> , 2011 , 59, 572-83	10.2	386
431	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021 , 79, 243-262	10.2	382
430	Urine markers for bladder cancer surveillance: a systematic review. <i>European Urology</i> , 2005 , 47, 736-48	10.2	372
429	Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. <i>American Journal of Pathology</i> , 2001 , 158, 1955-9	5.8	370
428	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	50.4	320
427	Androgen receptors in endocrine-therapy-resistant human prostate cancer. <i>International Journal of Cancer</i> , 1991 , 48, 189-93	7.5	312

426	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015 , 47, 736-45	36.3	306
425	Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2009 , 30, 327-34	5.6	278
424	Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1912-21	2.2	259
423	Molecular landmarks of tumor hypoxia across cancer types. <i>Nature Genetics</i> , 2019 , 51, 308-318	36.3	255
422	Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4178-86	2.2	250
421	The contemporary concept of significant versus insignificant prostate cancer. <i>European Urology</i> , 2011 , 60, 291-303	10.2	224
420	A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. <i>Journal of Urology</i> , 2011 , 185, 121-5	2.5	222
419	Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. <i>Radiology</i> , 2010 , 255, 485-94	20.5	220
418	FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. <i>PLoS ONE</i> , 2010 , 5, e13821	3.7	219
417	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , 2017 , 72, 250-266	10.2	218
416	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , 2014 , 15, 1521-1532	21.7	218
415	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019 , 176, 831-843.e236.2	36.2	214
414	Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. <i>Radiology</i> , 2008 , 249, 900-8	20.5	205
413	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017 , 72, 84-109	10.2	203
412	Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. <i>Human Pathology</i> , 1993 , 24, 819-32	3.7	187
411	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021 , 79, 263-282	10.2	186
410	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. <i>Modern Pathology</i> , 2011 , 24, 6-15	9.8	183
409	International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3206-12	2.2	182

408	FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. <i>Cancer Research</i> , 2004 , 64, 1911-4	10.1	180
407	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. <i>Modern Pathology</i> , 2011 , 24, 16-25	9.8	171
406	Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. <i>Modern Pathology</i> , 2015 , 28, 457-64	9.8	170
405	Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. <i>Cancer Research</i> , 2005 , 65, 5730-9	10.1	168
404	Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1050-8	9.7	164
403	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019 , 76, 43-51	10.2	163
402	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. <i>Human Molecular Genetics</i> , 2004 , 13, 1303-13	5.6	158
401	A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. <i>International Journal of Cancer</i> , 2002 , 102, 91-5	7.5	157
400	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , 2018 , 174, 564-575.e18	56.2	154
399	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology</i> , 2020 , 21, 222-232	21.7	154
398	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2299-2305	2.2	153
397	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. <i>Modern Pathology</i> , 2011 , 24, 26-38	9.8	152
396	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
395	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. <i>Modern Pathology</i> , 2011 , 24, 48-57	9.8	149
394	Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. <i>Vaccine</i> , 2001 , 19, 3700-9	4.1	133
393	Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. <i>European Urology</i> , 2010 , 58, 433-41	10.2	131
392	Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy. <i>Analytical Chemistry</i> , 2006 , 78, 7761-9	7.8	131
391	Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 684-93	6.7	131

390	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , 2017 , 8, 13671	17.4	128
389	Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. <i>European Urology</i> , 2010 , 57, 1111-4	10.2	124
388	Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. <i>European Urology</i> , 2008 , 54, 835-43	10.2	124
387	Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. <i>European Journal of Human Genetics</i> , 2002 , 10, 819-24	5.3	121
386	Do neuroendocrine cells in human prostate cancer express androgen receptor?. <i>Histochemistry</i> , 1993 , 100, 393-8		121
385	A new and highly prognostic system to discern T1 bladder cancer substage. <i>European Urology</i> , 2012 , 61, 378-84	10.2	117
384	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell</i> , 2018 , 173, 1003-1013.e15	56.2	115
383	Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. <i>Modern Pathology</i> , 2016 , 29, 630-6	9.8	113
382	Detection of factor VIII/coagulant antigen in human liver tissue. <i>Nature</i> , 1983 , 303, 530-2	50.4	111
381	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013 , 24, 1141-62	10.3	109
380	Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 1503-12	6.7	107
379	TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. <i>Nature Genetics</i> , 2017 , 49, 1336-1345	36.3	105
378	ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. <i>Modern Pathology</i> , 2012 , 25, 471-9	9.8	104
377	False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 35-43	6.7	101
376	The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. <i>European Urology</i> , 2006 , 50, 258-65	10.2	99
375	A Prostate Cancer "Nimbofus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017 , 72, 665-674	10.2	98
374	The Proteogenomic Landscape of Curable Prostate Cancer. <i>Cancer Cell</i> , 2019 , 35, 414-427.e6	24.3	97
373	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. <i>Modern Pathology</i> , 2011 , 24, 39-47	9.8	97

372	Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. <i>European Journal of Cancer</i> , 2014 , 50, 1610-6	7.5	95
371	Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. <i>European Journal of Cancer</i> , 2012 , 48, 1318-25	7.5	91
370	Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI. <i>Medical Physics</i> , 2010 , 37, 1873-83	4.4	91
369	Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. <i>Urology</i> , 2001 , 57, 83-90	1.6	91
368	The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. <i>International Journal of Cancer</i> , 1995 , 62, 252-8	7.5	91
367	Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. <i>Cancer</i> , 2012 , 118, 4053-62	6.4	90
366	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , 2011 , 108, 24-30	5.6	90
365	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 85-94	2.8	89
364	Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 3011-8	12.9	89
363	The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. <i>Journal of Urology</i> , 1997 , 158, 171-4	2.5	88
362	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 440, 3-11	5.1	87
361	Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. <i>Molecular Carcinogenesis</i> , 2016 , 55, 537-545	5	86
360	Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. <i>European Urology</i> , 2007 , 52, 89-97	10.2	86
359	Prostate cancer localization with multispectral MRI using cost-sensitive support vector machines and conditional random fields. <i>IEEE Transactions on Image Processing</i> , 2010 , 19, 2444-55	8.7	85
358	Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 1014-21	6.7	84
357	Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat. <i>Molecular and Cellular Endocrinology</i> , 1995 , 113, 245-53	4.4	84
356	Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1991 , 1073, 23-32	4	83
355	Defining the threshold for significant versus insignificant prostate cancer. <i>Nature Reviews Urology</i> , 2013 , 10, 473-82	5.5	82

354	Reconstitution of the thymus dependent area in the spleen of lethally irradiated mice. A light and electron microscopical study of the T-cell microenvironment. <i>Cell and Tissue Research</i> , 1974 , 149, 43-60	4.2	82
353	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020 , 44, e87-e99	6.7	82
352	Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. <i>BJU International</i> , 2008 , 101, 1106-10	5.6	81
351	Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 428-34	5.1	80
350	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015 , 28, 612-30	9.8	79
349	Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. <i>Prostate</i> , 2000 , 42, 34-44	4.2	79
348	Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. <i>Cancer Research</i> , 2008 , 68, 7541-9	10.1	78
347	A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. <i>European Urology</i> , 2013 , 63, 321-32	10.2	77
346	Association of tissue promoter methylation levels of APC, TGF β , HOXD3 and RASSF1A with prostate cancer progression. <i>International Journal of Cancer</i> , 2011 , 129, 2454-62	7.5	77
345	High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2005 , 44, 438-49	5	77
344	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019 , 76, 790-813	10.2	76
343	Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. <i>Journal of Urology</i> , 2015 , 193, 1519-24	2.5	75
342	Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. <i>Journal of Pathology</i> , 1990 , 160, 329-32	9.4	75
341	Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. <i>PLoS ONE</i> , 2009 , 4, e4830	3.7	74
340	Web-based virtual microscopy in teaching and standardizing Gleason grading. <i>Human Pathology</i> , 2005 , 36, 381-6	3.7	74
339	Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. <i>Cancer Prevention Research</i> , 2013 , 6, 483-94	3.2	73
338	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019 , 10, 278	17.4	72
337	Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. <i>International Journal of Cancer</i> , 1992 , 52, 581-4	7.5	72

- 336 Prostate cancer. *Nature Reviews Disease Primers*, **2021**, 7, 9 51.1 72
- 335 High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. *Prostate*, **2009**, 69, 1091-100 4.2 71
- 334 Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 1498-507 5.6 70
- 333 Contemporary grading for prostate cancer: implications for patient care. *European Urology*, **2013**, 63, 892-901 10.2 69
- 332 FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. *European Urology*, **2007**, 52, 760-8 10.2 67
- 331 Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. *International Journal of Cancer*, **2006**, 119, 1212-5 7.5 67
- 330 Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. *Urology*, **2000**, 56, 617-21 1.6 67
- 329 Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. *European Urology*, **2015**, 67, 64-70 10.2 66
- 328 Mitochondrial mutations drive prostate cancer aggression. *Nature Communications*, **2017**, 8, 656 17.4 66
- 327 Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. *European Urology*, **2013**, 64, 530-9 10.2 66
- 326 Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. *American Journal of Pathology*, **2001**, 158, 399-406 5.8 66
- 325 Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. *Journal of Clinical Oncology*, **2020**, 38, 1474-1494 2.2 66
- 324 Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. *Modern Pathology*, **2017**, 30, 1126-1132 9.8 65
- 323 Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). *European Urology*, **2009**, 55, 653-67 10.2 65
- 322 Does PSA velocity predict prostate cancer in pre-screened populations?. *European Urology*, **2006**, 49, 460-5; discussion 465 10.2 65
- 321 Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. *Cancer*, **2001**, 92, 768-75 6.4 65
- 320 Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. *European Urology*, **2013**, 64, 693-9 10.2 64
- 319 Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. *Genes Chromosomes and Cancer*, **1995**, 12, 241-50 5 64

318	Characterization of polyclonal antibodies against the N-terminal domain of the human androgen receptor. <i>Molecular and Cellular Endocrinology</i> , 1989 , 67, 29-38	4.4	64
317	Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. <i>European Urology</i> , 2013 , 63, 379-85	10.2	63
316	A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. <i>Human Pathology</i> , 2005 , 36, 981-6	3.7	63
315	Evaluation of prostate needle biopsies in a population-based screening study. <i>Cancer</i> , 1999 , 85, 145-152	6.4	62
314	Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. <i>Urology</i> , 2005 , 65, 745-9	1.6	61
313	Handling and pathology reporting of radical prostatectomy specimens. <i>European Urology</i> , 2003 , 44, 626-36	36.2	61
312	Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy. <i>Ophthalmology</i> , 1990 , 97, 1275-80	7.3	61
311	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
310	Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 1589-601	7.6	59
309	Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. <i>European Urology</i> , 2010 , 57, 821-9	10.2	59
308	Gleason score, age and screening: modeling dedifferentiation in prostate cancer. <i>International Journal of Cancer</i> , 2006 , 119, 2366-71	7.5	58
307	Gene expression profiling of the human prostate zones. <i>BJU International</i> , 2006 , 98, 886-97	5.6	58
306	Handling and pathology reporting of prostate biopsies. <i>European Urology</i> , 2004 , 46, 177-81	10.2	58
305	A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014 , 17, 252-8	6.2	57
304	Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. <i>PLoS ONE</i> , 2009 , 4, e5662	3.7	57
303	The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. <i>European Urology</i> , 2010 , 57, 1052-7	10.2	57
302	Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. <i>Human Pathology</i> , 1998 , 29, 1005-12	3.7	56
301	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016 , 69, 441-9	7.3	55

300	Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. <i>European Journal of Cancer</i> , 2016 , 66, 26-33	7.5	55
299	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. <i>BMC Cancer</i> , 2018 , 18, 8	4.8	54
298	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , 2017 , 77, 5479-5490	10.1	53
297	Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. <i>European Urology</i> , 2006 , 50, 475-82	10.2	53
296	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021 , 23, 87-98	23.4	53
295	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. <i>European Urology</i> , 2016 , 69, 802-20	10.2	52
294	Cellular and molecular pathology of prostate cancer precursors. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000 , 19-43		52
293	Primary cutaneous adenoid cystic carcinoma: case report, immunohistochemistry, and review of the literature. <i>British Journal of Dermatology</i> , 1988 , 118, 567-77	4	52
292	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , 2011 , 108, E237-44	5.6	51
291	Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. <i>World Journal of Urology</i> , 1997 , 15, 339-45	4	51
290	Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. <i>Urology</i> , 1999 , 53, 523-9	1.6	51
289	Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?. <i>American Journal of Clinical Pathology</i> , 2009 , 131, 279-83	1.9	50
288	Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. <i>Journal of Biological Chemistry</i> , 2012 , 287, 34019-31	5.4	50
287	DNA methylation of HOXD3 as a marker of prostate cancer progression. <i>Laboratory Investigation</i> , 2010 , 90, 1060-7	5.9	49
286	Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. <i>American Journal of Pathology</i> , 1999 , 154, 543-51	5.8	49
285	Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. <i>BJU International</i> , 2012 , 110, 1169-76	5.6	48
284	Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. <i>European Urology</i> , 2014 , 66, 841-8	10.2	46
283	Impact of 5 α -reductase inhibitors on men followed by active surveillance for prostate cancer. <i>European Urology</i> , 2011 , 59, 509-14	10.2	46

282	Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. <i>Genes Chromosomes and Cancer</i> , 2004 , 39, 249-56	5	46
281	Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. <i>Prostate</i> , 2002 , 50, 203-15	4.2	46
280	Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. <i>European Urology</i> , 2017 , 72, 45-51	10.2	45
279	Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. <i>Laboratory Investigation</i> , 2000 , 80, 1291-8	5.9	45
278	Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 2896-904	12.9	44
277	Lesions predictive for prostate cancer in a screened population: first and second screening round findings. <i>Prostate</i> , 2004 , 61, 260-6	4.2	44
276	Nerve outgrowth and neuropeptide expression during the remodeling of human burn wound scars. A 7-month follow-up study of 22 patients. <i>Burns</i> , 2001 , 27, 717-22	2.3	44
275	Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. <i>Urological Research</i> , 1995 , 22, 333-41		44
274	Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. <i>Urological Research</i> , 1990 , 18, 181-7		44
273	Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. <i>JAMA Oncology</i> , 2020 , 6, 1372-1380	13.4	44
272	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020 , 6, 231-234	5.1	44
271	Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. <i>European Urology</i> , 2014 , 66, 619-22	10.2	43
270	Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. <i>European Urology</i> , 2010 , 57, 256-66	10.2	43
269	The New Realization About Cribriform Prostate Cancer. <i>Advances in Anatomic Pathology</i> , 2018 , 25, 31-37	5.1	42
268	ShatterProof: operational detection and quantification of chromothripsis. <i>BMC Bioinformatics</i> , 2014 , 15, 78	3.6	42
267	Pathological stage review is indicated in primary pT1 bladder cancer. <i>BJU International</i> , 2010 , 106, 206-11	3.6	42
266	Decreased expression of CD44 in metastatic prostate cancer. <i>International Journal of Cancer</i> , 1999 , 84, 478-83	7.5	41
265	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 395-406	5.1	40

264	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <i>Prostate</i> , 2015 , 75, 1277-84	4.2	40
263	The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. <i>Journal of Pathology</i> , 2009 , 218, 104-12	9.4	40
262	Should we replace the Gleason score with the amount of high-grade prostate cancer?. <i>European Urology</i> , 2007 , 51, 931-9	10.2	40
261	Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. <i>International Journal of Cancer</i> , 1999 , 80, 439-43	7.5	40
260	Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. <i>Prostate</i> , 2014 , 74, 372-80	4.2	39
259	Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 463, 367-77	5.1	39
258	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 295-302	302	39
257	Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. <i>European Urology</i> , 2011 , 59, 1026-31	10.2	39
256	Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 169-77	6.7	39
255	HISTOPATHOLOGICAL PROSTATE CANCER CHARACTERISTICS AT RADICAL PROSTATECTOMY AFTER POPULATION BASED SCREENING. <i>Journal of Urology</i> , 2000 , 164, 411-415	2.5	39
254	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012 , 7, 1037-45	5.7	38
253	NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. <i>Clinical Cancer Research</i> , 2012 , 18, 308-16	12.9	38
252	Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. <i>Cancer</i> , 2001 , 92, 3120-9	6.4	38
251	A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. <i>Nature Communications</i> , 2018 , 9, 3510	17.4	37
250	Real-Time MRI-Guided Focused Ultrasound for Focal Therapy of Locally Confined Low-Risk Prostate Cancer: Feasibility and Preliminary Outcomes. <i>American Journal of Roentgenology</i> , 2015 , 205, W177-84	5.4	36
249	Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015 , 148, 156-65	5.1	36
248	Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics. <i>Prostate</i> , 2007 , 67, 154-61	4.2	36
247	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. <i>Cancer</i> , 2008 , 112, 636-44	6.4	36

246	No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. <i>British Journal of Cancer</i> , 1991 , 64, 411-3	8.7	36
245	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016 , 27, 1311-6	10.3	36
244	Young-age prostate cancer. <i>Journal of Clinical Pathology</i> , 2015 , 68, 511-5	3.9	35
243	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , 2014 , 18, 333-42	2.2	35
242	Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). <i>Prostate</i> , 2001 , 47, 252-61	4.2	35
241	Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. <i>Urologia Internationalis</i> , 1998 , 60, 17-24	1.9	35
240	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. <i>Histopathology</i> , 2014 , 65, 216-27	7.3	34
239	TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. <i>Clinical Cancer Research</i> , 2013 , 19, 5202-9	12.9	34
238	Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract. <i>Oncogene</i> , 2006 , 25, 2113-8	9.2	34
237	Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. <i>Cancer Genetics and Cytogenetics</i> , 1994 , 73, 60-4		34
236	Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. <i>Scientific Reports</i> , 2014 , 4, 4432	4.9	33
235	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4025-36	15.9	33
234	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , 2017 , 197, 75-83	2.5	32
233	Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. <i>Laboratory Investigation</i> , 2003 , 83, 789-96	5.9	32
232	Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. <i>BJU International</i> , 2012 , 110, 980-6	5.6	31
231	Cytology and Urinary Markers for the Diagnosis of Bladder Cancer. <i>European Urology Supplements</i> , 2009 , 8, 536-541	0.9	31
230	Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 938-46	6.7	31
229	Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 442, 211-7	5.1	31

228	An in vitro model of urothelial regeneration: effects of growth factors and extracellular matrix proteins. <i>Journal of Pathology</i> , 1994 , 173, 283-91	9.4	31
227	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. <i>European Urology</i> , 2020 , 77, 191-198	10.2	31
226	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2017 , 197, 335-341	2.5	30
225	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <i>Histopathology</i> , 2013 , 63, 756-66	7.3	30
224	Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. <i>International Journal of Cancer</i> , 1997 , 71, 284-91	7.5	30
223	The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. <i>Diagnostic Cytopathology</i> , 2006 , 34, 523-7	1.4	30
222	Renal oncocyoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?. <i>Journal of Clinical Pathology</i> , 2007 , 60, 585-6	3.9	30
221	Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. <i>European Urology</i> , 2005 , 48, 153-61	10.2	30
220	Staging prostate cancer. <i>Microscopy Research and Technique</i> , 2000 , 51, 423-9	2.8	30
219	Validation of stem cell markers in clinical prostate cancer: β -integrin is predictive for non-aggressive disease. <i>Prostate</i> , 2014 , 74, 488-96	4.2	29
218	Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?. <i>BJU International</i> , 2009 , 104, 41-7	5.6	29
217	Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. <i>Blood</i> , 2008 , 112, 1844-52	2.2	29
216	Epidermal growth factor receptor regulates normal urothelial regeneration. <i>Laboratory Investigation</i> , 2003 , 83, 1333-41	5.9	29
215	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. <i>Molecular Metabolism</i> , 2019 , 25, 119-130	8.8	28
214	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017 , 72, 22-31	10.2	28
213	Tumour features in the control and screening arm of a randomized trial of prostate cancer. <i>European Urology</i> , 2006 , 50, 70-5	10.2	28
212	Characterization of distinct functions for growth factors in murine transitional epithelial cells in primary organotypic culture. <i>Experimental Cell Research</i> , 1994 , 214, 510-8	4.2	28
211	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019 , 30, 1697-1727	10.3	28

210	Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer. <i>European Urology</i> , 2014 , 66, 982-6	10.2	27
209	A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. <i>European Urology</i> , 2014 , 66, 406-13	10.2	27
208	Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience. <i>Canadian Urological Association Journal</i> , 2012 , 6, 283	1.2	27
207	Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. <i>BJU International</i> , 2011 , 107, 540-6	5.6	27
206	Epidermal participation in post-burn hypertrophic scar development. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999 , 434, 221-6	5.1	27
205	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. <i>Modern Pathology</i> , 2015 , 28, 695-705	9.8	26
204	Prognostic prostate tissue biomarkers of potential clinical use. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 293-300	5.1	26
203	Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway. <i>Histopathology</i> , 2017 , 70, 281-289	7.3	26
202	Phenotypic and genotypic analysis of large-cell lymphomas, formerly classified as true histiocytic lymphoma: identification of an unusual group of tumors. <i>Leukemia Research</i> , 1990 , 14, 337-46	2.7	26
201	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019 , 25, 1615-1626	50.5	25
200	Prognostic markers in nephroblastoma (Wilms' tumor). <i>Urology</i> , 2005 , 65, 1047-54	1.6	25
199	Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. <i>Urology</i> , 2006 , 68, 615-20	1.6	25
198	Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. <i>Prostate</i> , 2006 , 66, 625-31	4.2	25
197	Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. <i>Human Pathology</i> , 1999 , 30, 1328-35	3.7	25
196	NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. <i>Oncotarget</i> , 2014 , 5, 11081-90	3.3	25
195	Grading of prostate cancer: a work in progress. <i>Histopathology</i> , 2019 , 74, 146-160	7.3	25
194	Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. <i>European Journal of Cancer</i> , 2010 , 46, 3068-72	7.5	24
193	The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. <i>Journal of Urology</i> , 1997 , 158, 1880-4; discussion 1884-5	2.5	24

192	Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 138-144	2.8	24
191	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , 2016 , 93, 77-85	1.6	23
190	Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer?. <i>Prostate</i> , 2013 , 73, 442-8	4.2	23
189	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 107-13	19.4	23
188	MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. <i>Clinical Cancer Research</i> , 2004 , 10, 591-7	12.9	23
187	Androgen pathway dysregulation in BRCA1-mutated breast tumors. <i>Breast Cancer Research and Treatment</i> , 2003 , 79, 121-7	4.4	23
186	Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. <i>Cancer</i> , 2005 , 103, 708-16	6.4	23
185	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , 2019 , 74, 474-482	7.3	23
184	Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. <i>Translational Oncology</i> , 2017 , 10, 168-177	4.9	22
183	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. <i>Journal of Urology</i> , 2018 , 200, 104-113	2.5	22
182	Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3450-61	12.9	22
181	Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue. <i>Journal of Clinical Pathology</i> , 2012 , 65, 729-34	3.9	22
180	Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. <i>Current Opinion in Urology</i> , 2009 , 19, 516-21	2.8	22
179	Functions of epidermal growth factor-like growth factors during human urothelial reepithelialization in vitro and the role of erbB2. <i>Urological Research</i> , 2002 , 30, 240-7		22
178	Serendipity in detecting disease in low prostate-specific antigen ranges. <i>BJU International</i> , 2002 , 89, 384-9	5.6	22
177	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , 2021 , 34, 660-671	9.8	22
176	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2020 , 44, e15-e29	6.7	21
175	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. <i>Nature Communications</i> , 2020 , 11, 441	17.4	21

174	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. <i>Cancer Cell</i> , 2019 , 36, 674-689.e6	24.3	21
173	Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. <i>Prostate</i> , 2012 , 72, 108-15	4.2	21
172	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2019 , 230-238	1.2	21
171	microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017 , 167, 192-202	5.1	20
170	Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. <i>Journal of Pathology</i> , 2014 , 233, 148-58	9.4	20
169	Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. <i>Urology</i> , 2014 , 83, 81-7	1.6	20
168	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. <i>BJU International</i> , 2012 , 109, 70-6	5.6	20
167	Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: a MIB-1/GFAP double labeling study. <i>Acta Neuropathologica</i> , 1996 , 91, 99-103	14.3	20
166	Migration of B lymphocytes in lymphoid organs of lethally irradiated, thymocyte-reconstituted mice. <i>Cell and Tissue Research</i> , 1980 , 212, 497-508	4.2	20
165	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 84-91	4	20
164	Utility of Pathology Imagebase for standardisation of prostate cancer grading. <i>Histopathology</i> , 2018 , 73, 8-18	7.3	19
163	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. <i>European Radiology</i> , 2018 , 28, 4281-4287	8	19
162	The mTOR Targets 4E-BP1/2 Restrains Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer. <i>Molecular Cancer Research</i> , 2018 , 16, 682-695	6.6	18
161	Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. <i>Journal of Urology</i> , 2010 , 184, 81-6	2.5	18
160	Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. <i>BJU International</i> , 2001 , 88, 147-57	5.6	18
159	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 630-637	6.2	17
158	Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. <i>Journal of Clinical Pathology</i> , 2013 , 66, 779-86	3.9	17
157	Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. <i>Cancer</i> , 2004 , 100, 968-75	6.4	17

156	Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001 , 439, 552-9	5.1	17
155	Ultrastructural and immunohistochemical segregation of gemistocytic subsets. <i>Human Pathology</i> , 1991 , 22, 33-40	3.7	17
154	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges. <i>American Journal of Surgical Pathology</i> , 2020 , 44, e30-e46	6.7	16
153	Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. <i>Clinical Epigenetics</i> , 2016 , 8, 32	7.7	16
152	Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. <i>Prostate</i> , 2011 , 71, 778-90	4.2	16
151	Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?. <i>BJU International</i> , 2008 , 101, 283-8	5.6	16
150	Peptidylglycine alpha-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate. <i>International Journal of Cancer</i> , 2001 , 94, 28-34	7.5	16
149	Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. <i>Oncotarget</i> , 2014 , 5, 7858-69	3.3	16
148	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 673-680	6.7	16
147	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , 2020 , 125, 525-530	5.6	16
146	Downgrading of biopsy based Gleason score in prostatectomy specimens. <i>Journal of Clinical Pathology</i> , 2014 , 67, 313-8	3.9	15
145	Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. <i>Journal of Pathology</i> , 1998 , 186, 406-9	9.4	15
144	Prostatic preneoplasia and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2008 , 1785, 156-811	11.2	15
143	Androgen-independent expression of adrenomedullin and peptidylglycine alpha-amidating monooxygenase in human prostatic carcinoma. <i>Molecular Carcinogenesis</i> , 2003 , 38, 14-24	5	15
142	Secondary delayed-type hypersensitivity to sheep red blood cells in mice: a long-lived memory phenomenon. <i>Cellular Immunology</i> , 1977 , 34, 385-94	4.4	15
141	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2020 , 44, e66-e79	6.7	14
140	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. <i>Oncology Letters</i> , 2017 , 14, 390-396	2.6	14
139	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.. <i>Nature Medicine</i> , 2022 ,	50.5	14

138	Monoclonal antibodies for immunohistochemical labeling of immunocompetent cells in frozen sections of rhesus monkey tissues. <i>Journal of Medical Primatology</i> , 1991 , 20, 386-393	0.7	14
137	Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma. <i>Human Pathology</i> , 2019 , 85, 313-327	3.7	14
136	On cribriform prostate cancer. <i>Translational Andrology and Urology</i> , 2018 , 7, 145-154	2.3	14
135	Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. <i>Anticancer Research</i> , 2012 , 32, 259-63	2.3	14
134	Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?. <i>Histopathology</i> , 2017 , 71, 926-933	7.3	13
133	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	12
132	Expression and prognostic value of platelet-derived growth factor-AA and its receptor in nephroblastoma. <i>BJU International</i> , 2010 , 106, 1389-93	5.6	12
131	Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. <i>Prostate</i> , 1995 , 27, 154-9	4.2	12
130	Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice. <i>PLoS ONE</i> , 2016 , 11, e0147500	3.7	12
129	The value of triple antibody (34β12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins. <i>Journal of Clinical Pathology</i> , 2012 , 65, 437-40	3.9	11
128	Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin. <i>Journal of Urology</i> , 2008 , 179, 2014-9	2.5	11
127	Infrequent microsatellite instability in urothelial cell carcinoma of the bladder in young patients. <i>European Urology</i> , 2006 , 49, 685-90	10.2	11
126	Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. <i>International Journal of Cancer</i> , 2006 , 118, 2538-42	7.5	11
125	Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5671-2	2.2	11
124	Characterization of mouse urothelial cell lines in different phases of transitional-cell carcinogenesis. <i>International Journal of Cancer</i> , 1993 , 54, 1022-7	7.5	11
123	Enhancement by prostaglandin E1 and essential fatty acid deficiency of the passive transfer of delayed hypersensitivity to PPD in rats. Comparison with effects on delayed hypersensitivity to SRBC in mice. <i>International Journal of Immunopharmacology</i> , 1979 , 1, 119-26		11
122	Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy. <i>Journal of Urology</i> , 2017 , 198, 79-85	2.5	10
121	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 777-786	5.1	10

120	Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3+4=7 and highest Gleason score 3+4=7 or >3+4=7. <i>Histopathology</i> , 2018 , 72, 760-765	7.3	10
119	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , 2014 , 8, 47-52	1.2	10
118	Clinicopathologic characteristics of 23 cases of invasive low-grade papillary urothelial carcinoma. <i>Urology</i> , 2012 , 80, 361-6	1.6	10
117	Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. <i>Prostate</i> , 2012 , 72, 1295-305	4.2	10
116	Secondary delayed type hypersensitivity to sheep red blood cells in mice: dependence on long-lived memory cells. <i>Cellular Immunology</i> , 1979 , 43, 94-102	4.4	10
115	Primary and secondary delayed-type hypersensitivity to minor histocompatibility antigens in the mouse. <i>Cellular Immunology</i> , 1979 , 47, 182-91	4.4	10
114	Technical Note: Method to correlate whole-specimen histopathology of radical prostatectomy with diagnostic MR imaging. <i>Medical Physics</i> , 2016 , 43, 1065-72	4.4	10
113	Lymph node staging in prostate cancer: perspective for the pathologist. <i>Journal of Clinical Pathology</i> , 2016 , 69, 1039-1045	3.9	10
112	Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. <i>European Urology</i> , 2019 , 75, 374-377	10.2	10
111	Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. <i>World Journal of Urology</i> , 2016 , 34, 253-60	4	9
110	Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens. <i>Histopathology</i> , 2020 , 77, 742-748	7.3	9
109	In vitro modulation of implantation and intraepithelial expansion of bladder tumor cells by epidermal growth factor. <i>Experimental Cell Research</i> , 1997 , 235, 395-402	4.2	9
108	Differential responsiveness to Mls locus antigens in graft-versus-host and host-versus-graft reactions. <i>Cellular Immunology</i> , 1980 , 51, 215-25	4.4	9
107	Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 521-534	5.1	9
106	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , 2021 , 298, 695-703	20.5	9
105	MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison with T ₂ , T ₁ and ADC. <i>Physics in Medicine and Biology</i> , 2017 , 62, 1126-1148	3.8	8
104	Long-term oncological outcomes of patients with paratesticular sarcoma. <i>BJU International</i> , 2019 , 124, 801-810	5.6	8
103	Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. <i>Clinical Epigenetics</i> , 2019 , 11, 54	7.7	8

102	Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates?. <i>Urology</i> , 2013 , 82, 405-9	1.6	8
101	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , 2020 , 17, e1003281	11.6	8
100	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>European Urology Focus</i> , 2021 ,	5.1	8
99	SIU-ICUD on bladder cancer: pathology. <i>World Journal of Urology</i> , 2019 , 37, 41-50	4	8
98	Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer. <i>Urology Case Reports</i> , 2018 , 16, 98-100	0.5	8
97	Effect of material property heterogeneity on biomechanical modeling of prostate under deformation. <i>Physics in Medicine and Biology</i> , 2015 , 60, 195-209	3.8	7
96	Granular necrosis: a distinctive form of cell death in malignant tumours. <i>Pathology</i> , 2020 , 52, 507-514	1.6	7
95	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 603.e1-603.e7	2.8	7
94	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , 2017 , 11, 41-46	1.2	7
93	Striated muscle in the prostatic apex: does the amount in radical prostatectomy specimens predict postprostatectomy urinary incontinence?. <i>Urology</i> , 2014 , 83, 888-92	1.6	7
92	Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours. <i>Journal of Pathology</i> , 1998 , 185, 273-83	9.4	7
91	Modulation of intra-epithelial expansion of human T24 bladder-carcinoma cells in murine urothelium by growth factors and extracellular-matrix components. <i>International Journal of Cancer</i> , 1995 , 60, 707-11	7.5	7
90	Clonality of localized and metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2016 , 26, 219-24	2.8	7
89	GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. <i>European Urology Oncology</i> , 2019 , 2, 231-238	6.7	7
88	Association between metformin medication, genetic variation and prostate cancer risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 96-105	6.2	7
87	SeqControl: process control for DNA sequencing. <i>Nature Methods</i> , 2014 , 11, 1071-5	21.6	6
86	Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression. <i>Journal of Urology</i> , 2014 , 192, 1088-93	2.5	6
85	Fixation-dependent immunolocalization shift and immunoreactivity of intracellular growth factors in cartilage. <i>The Histochemical Journal</i> , 2000 , 32, 391-6		6

84	Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2020 , 33, 700-712	9.8	6
83	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2020 ,	6.7	6
82	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021 ,	5.1	6
81	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1118-1126	6.7	6
80	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 39.e1-39.e9	2.8	6
79	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018 , 18, 78	2.2	6
78	4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2013 , 61, 500-9	3.4	5
77	Metastatic clear cell renal cell carcinoma presenting as multiple colonic polyps. <i>International Journal of Surgical Pathology</i> , 2011 , 19, 791-4	1.2	5
76	Hepatic rhabdomyomatous tumor: late sequel of a fetal rhabdomyomatous nephroblastoma. <i>Pediatric Pathology</i> , 1992 , 12, 449-56		5
75	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020 , 204, 1187-1194	2.5	5
74	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019 , 75, 699-702	10.2	5
73	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021 , 300, 369-379	20.5	5
72	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Urothology. <i>Histopathology</i> , 2019 , 74, 844-852	7.3	4
71	Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2015 , 18, 69-74	6.2	4
70	Assessment of intravascular granulomas in testicular seminomas and their association with tumour relapse and dissemination. <i>Journal of Clinical Pathology</i> , 2016 , 69, 47-52	3.9	4
69	Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 237-40	4	4
68	Differential responsiveness to H-2-subregion-coded antigens in graft versus host and host versus graft reactions. <i>Cellular Immunology</i> , 1981 , 57, 389-99	4.4	4
67	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6: Prebiopsy MRI: Through the Looking Glass. <i>European Urology</i> , 2020 , 78, 310-313	10.2	4

66	Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. <i>Pathology Research and Practice</i> , 2020 , 216, 153186	3.4	4
65	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. <i>Annals of Diagnostic Pathology</i> , 2021 , 52, 151733	2.2	4
64	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019 , 2, 333-336	6.7	4
63	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 61-66	4	3
62	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 88-96	6.7	3
61	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020 , 14, E373-E382	1.2	3
60	Single Prostatic Cancer Foci on Prostate Biopsy. <i>European Urology Supplements</i> , 2008 , 7, 549-556	0.9	3
59	How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008 , 175-84		3
58	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. <i>Nature Communications</i> , 2021 , 12, 6248	17.4	3
57	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). <i>American Journal of Surgical Pathology</i> , 2019 , 43, e1-e12	6.7	3
56	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 30-39	5.1	3
55	Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 69-76	6.2	3
54	Intraductal carcinoma of the prostate is not a diagnostic entity. <i>Histopathology</i> , 2021 , 78, 342-344	7.3	3
53	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.. <i>European Urology</i> , 2021 ,	10.2	3
52	Re: should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. <i>European Urology</i> , 2012 , 61, 220	10.2	2
51	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 604.e17-604.e24	2.8	2
50	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. <i>Cancer Research</i> , 2021 , 81, 5833-5848	10.1	2
49	Detection of clinically significant prostate cancer with F-DCFPyL PET/multiparametric MR. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3702-3711	8.8	2

48	Human Microtumors Generated in 3D: Novel Tools for Integrated In Situ Studies of Cancer Immunotherapies. <i>Methods in Molecular Biology</i> , 2016 , 1393, 147-61	1.4	2
47	Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases. <i>Journal of Clinical Pathology</i> , 2019 , 72, 363-367	3.9	2
46	Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. <i>European Journal of Cancer</i> , 2021 , 148, 432-439	7.5	2
45	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. <i>World Journal of Urology</i> , 2021 , 1	4	2
44	Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation 1999 , 80, 439		2
43	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2019 , 75, 453-467	7.3	1
42	The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 859-861	6.7	1
41	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018 , 200, 1056-1061	2.5	1
40	The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. <i>Urology</i> , 2014 , 84, 1073-80	1.6	1
39	Re: Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. <i>European Urology</i> , 2014 , 66, 174	10.2	1
38	Pathological staging of bladder cancer. <i>Diagnostic Histopathology</i> , 2013 , 19, 366-375	0.7	1
37	Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>Eur Urol</i> 2014 , 66, 570-573	10.2	1
36	Words of wisdom. Re: The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. <i>European Urology</i> , 2010 , 58, 796-7	10.2	1
35	The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes.. <i>Pathology</i> , 2022 ,	1.6	1
34	SU-E-J-95: Towards Optimum Boundary Conditions for Biomechanical Model Based Deformable Registration Using Intensity Based Image Matching for Prostate Correlative Pathology. <i>Medical Physics</i> , 2012 , 39, 3674	4.4	1
33	The Clinical Genomics of Prostate Cancer 2017 , 97-110		1
32	Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2020 ,	5	1
31	Borderline Gleason scores: communication is the key. <i>Journal of Clinical Pathology</i> , 2020 , 73, 616-617	3.9	1

30	Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report. <i>Prostate</i> , 2021 , 81, 553-559	4.2	1
29	Gleason grade 5 prostate cancer: sub-patterns and prognosis. <i>Pathology</i> , 2021 , 53, 3-11	1.6	1
28	Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology 2008 , 30, 309-15		1
27	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020 , 6, 363-392	1	0
26	Impact of multidisciplinary bladder cancer care for muscle invasive bladder cancer: A propensity score matched analysis of survival outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 455-455	2.2	0
25	The telomere length landscape of prostate cancer. <i>Nature Communications</i> , 2021 , 12, 6893	17.4	0
24	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , 2021 , 16, e0259272	3.7	0
23	Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study. <i>BJU International</i> , 2021 , 129, 258	5.6	0
22	Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>Eur Urol Focus</i> . In press. https://doi.org/10.1016/j.euf.2021.03.017 . Focus on Our Personal Recollections and Observations.	5.1	0
21	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1007	6.7	0
20	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.. <i>European Radiology</i> , 2022 , 1	8	0
19	Editorial Comment. <i>Journal of Urology</i> , 2018 , 199, 1509	2.5	
18	Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology. <i>European Urology</i> , 2018 , 73, 139	10.2	
17	Words of wisdom. Re: Modeling grade progression in an active surveillance study. <i>European Urology</i> , 2014 , 66, 389-90	10.2	
16	De klinische relevantie van cribriforme en intraductale prostaatkanker in diagnostische naaldbiopsen. <i>Tijdschrift Voor Urologie</i> , 2017 , 7, 168-177	0.2	
15	Anatomo-Pathology 2012 , 39-54		
14	Should Pathologists Diagnose Adenocarcinoma When They Encounter a Single Small Atypical Focus in a Prostate Biopsy?. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 1072	6.7	
13	Editorial Comment. <i>Journal of Urology</i> , 2020 , 203, 318	2.5	

11	Genomic architecture of radioresistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 26-26	2.2
10	Integrated somatic subtypes of localized intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e560-e560	2.2
9	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16003-e16003	2.2
8	Nonneoplastic and Neoplastic Ureteral and Renal Pelvis Disease 2012 , 255-280	
7	Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 26-26	2.2
6	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , 2019 , E292-E299	1.2
5	Reply to Eva Comp�at, Mahul Amin, Victor Reuter's Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. <i>Eur Urol</i> 2019;76:413-5: Precision Medicine Responder. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 22-22	10.2
4	Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. <i>Canadian Association of Radiologists Journal</i> , 2021 , 72, 750-758	3.9
3	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 5.e1-5.e13	2.8
2	Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population Level. <i>Journal of Urology</i> , 2021 , 101097JU00000000000000002229	2.5
1	Penile Extramammary Paget Disease Associated With Urothelial Carcinoma In Situ: Case Report And Literature Review.. <i>Journal of Cutaneous Pathology</i> , 2022 ,	1.7